Literature DB >> 20675563

Angiotensin-(1-7) upregulates cardiac nitric oxide synthase in spontaneously hypertensive rats.

María A Costa1, María A Lopez Verrilli, Karina A Gomez, Pablo Nakagawa, Clara Peña, Cristina Arranz, Mariela M Gironacci.   

Abstract

It has been shown that angiotensin (ANG)-(1-7) activates nitric oxide synthase (NOS) in isolated ventricular myocytes from normotensive rats. Since many ANG-(1-7) actions are enhanced in situations of increased ANG II activity, as in hypertension, in this study we investigated the in vivo effect of ANG-(1-7) on NOS activity and expression of endothelial (eNOS), neuronal (nNOS), and inducible NOS (iNOS) in ventricles from spontaneously hypertensive rats (SHR). Rats were subjected to a 60-min ANG-(1-7) infusion (0.35 nmol/min); controls received saline. NOS activity was measured using the NADPH diaphorase histochemical method and by the conversion of L-[(14)C]arginine to citrulline, and NOS phosphorylation and expression were determined using Western blotting. In SHR, ANG-(1-7) infusion diminished mean arterial pressure from 180 ± 9 to 146 ± 9 mmHg (P < 0.05), and this effect was prevented by nitro-l-arginine methyl ester (l-NAME), a NOS inhibitor. In addition, NOS activity and eNOS phosphorylation were increased by ANG-(1-7) infusion. Ventricular eNOS and nNOS expression were increased 67.4 ± 6.4 and 51 ± 10%, respectively, by ANG-(1-7), whereas iNOS was not changed. In another set of experiments, we evaluated the mechanism by which ANG-(1-7) modifies NOS activity. Isolated ventricle slices preincubated with ANG-(1-7) showed an increase in NOS activity and eNOS phosphorylation, which was blocked by an AT(2) and a bradykinin B(2) receptor antagonist, but not by the Mas receptor antagonist. Our results show that in rats in a hypertensive state, ANG-(1-7) infusion upregulates cardiac NOS expression and activity through an AT(2)- and bradykinin-dependent mechanism. In this way ANG-(1-7) may elicit its cardioprotective action and contribute to some of the counterregulatory AT(2) receptor effects that oppose the AT(1) receptor-mediated effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20675563     DOI: 10.1152/ajpheart.00850.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  16 in total

1.  Angiotensin-(1-7) inhibits neuronal activity of dorsolateral periaqueductal gray via a nitric oxide pathway.

Authors:  Jihong Xing; Jian Kong; Jian Lu; Jianhua Li
Journal:  Neurosci Lett       Date:  2012-06-19       Impact factor: 3.046

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 3.  Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke.

Authors:  Douglas M Bennion; Emily Haltigan; Robert W Regenhardt; U Muscha Steckelings; Colin Sumners
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

4.  Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow.

Authors:  N M Mordwinkin; C J Meeks; S S Jadhav; T Espinoza; N Roda; G S diZerega; S G Louie; K E Rodgers
Journal:  Endocrinology       Date:  2012-03-20       Impact factor: 4.736

5.  Angiotensin 1-7 reduces mortality and rupture of intracranial aneurysms in mice.

Authors:  Ricardo A Peña Silva; David K Kung; Ian J Mitchell; Natalia Alenina; Michael Bader; Robson A S Santos; Frank M Faraci; Donald D Heistad; David M Hasan
Journal:  Hypertension       Date:  2014-05-05       Impact factor: 10.190

6.  Chronic treatment with angiotensin-(1-7) improves renal endothelial dysfunction in apolipoproteinE-deficient mice.

Authors:  J Stegbauer; S A Potthoff; I Quack; E Mergia; T Clasen; S Friedrich; O Vonend; M Woznowski; E Königshausen; L Sellin; L C Rump
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

7.  Heteromerization Between the Bradykinin B2 Receptor and the Angiotensin-(1-7) Mas Receptor: Functional Consequences.

Authors:  Bruno D Cerrato; Oscar A Carretero; Brana Janic; Hernán E Grecco; Mariela M Gironacci
Journal:  Hypertension       Date:  2016-08-22       Impact factor: 10.190

Review 8.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

9.  Role of angiotensin-(1-7) and Mas-R-nNOS pathways in amplified neuronal activity of dorsolateral periaqueductal gray after chronic heart failure.

Authors:  Jihong Xing; Jian Lu; Jianhua Li
Journal:  Neurosci Lett       Date:  2014-01-25       Impact factor: 3.046

Review 10.  Vascular endothelial dysfunction and pharmacological treatment.

Authors:  Jin Bo Su
Journal:  World J Cardiol       Date:  2015-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.